Vantage logo

Gantenerumab fails to Graduate

Roche’s Alzheimer’s antibody looks likely to join the scrapheap. But the company is determined to keep plugging away at the disease.

Vantage logo

Gossamer could put pressure on Merck

The pharma giant leads the pulmonary arterial hypertension pipeline, but other potentially disease-modifying treatments are in the works.